At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Post-Mkt 06-03 17:15:39 EDT
155.99
+4.68
+3.09%
盘后155.50
-0.49-0.31%
17:11 EDT
High156.87Low151.52Vol2.00M
Open151.57D1 Closing151.31Amplitude3.54%
Mkt Cap33.16BTradable Cap29.48BTotal Shares212.59M
T/O310.54MT/O Rate1.06%Tradable Shares189.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says
MT Newswires Live  ·  06-02 23:34
Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says
Movement Alert｜Revolution Medicines Falls 5.13% in Regular Trading, Profit-Taking After ASCO Pancreatic Cancer Data Rally
Market Focus  ·  06-02 22:40
Movement Alert｜Revolution Medicines Falls 5.13% in Regular Trading, Profit-Taking After ASCO Pancreatic Cancer Data Rally
Analyst Reiterates Buy on Revolution Medicines Amid Strong ASCO Feedback and Optimism for RAS-Targeted Solid Tumor Portfolio
TIPRANKS  ·  06-02 20:56
Analyst Reiterates Buy on Revolution Medicines Amid Strong ASCO Feedback and Optimism for RAS-Targeted Solid Tumor Portfolio
Revolution Medicines price target raised to $182 from $165 at RBC Capital
TIPRANKS  ·  06-02 20:39
Revolution Medicines price target raised to $182 from $165 at RBC Capital
U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik
Reuters  ·  06-02 15:49
U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik
Movement Alert｜Revolution Medicines Rises 5.11% in Regular Trading, ASCO Phase 3 Pancreatic Cancer Data Continues to Boost Stock
Market Focus  ·  06-02 02:53
Movement Alert｜Revolution Medicines Rises 5.11% in Regular Trading, ASCO Phase 3 Pancreatic Cancer Data Continues to Boost Stock
Revolution Medicines Is Maintained at Outperform by Oppenheimer
Dow Jones  ·  06-02 00:29
Revolution Medicines Is Maintained at Outperform by Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Apple, JetBlue, Cognizant
Reuters  ·  06-01 23:43
BUZZ-U.S. STOCKS ON THE MOVE-Apple, JetBlue, Cognizant
Oppenheimer Adjusts Revolution Medicines PT to $195 From $165, Maintains Outperform Rating
MT Newswires Live  ·  06-01 20:40
Oppenheimer Adjusts Revolution Medicines PT to $195 From $165, Maintains Outperform Rating
Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $195 From $165
THOMSON REUTERS  ·  06-01 20:24
Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $195 From $165
Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
TIPRANKS  ·  06-01 20:15
Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-01 20:00
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Remains a Buy on Revolution Medicines (RVMD)
TIPRANKS  ·  06-01 19:59
Oppenheimer Remains a Buy on Revolution Medicines (RVMD)
Summit drops as concerns over older patients cloud cancer trial data
Reuters  ·  06-01 19:37
Summit drops as concerns over older patients cloud cancer trial data
BUZZ-U.S. STOCKS ON THE MOVE -Revolution Medicines, FedEx, Xpeng
Reuters  ·  06-01 19:36
BUZZ-U.S. STOCKS ON THE MOVE -Revolution Medicines, FedEx, Xpeng
MORNING BID AMERICAS-AI and 1984
Reuters  ·  06-01 18:32
MORNING BID AMERICAS-AI and 1984
Revolution Medicines Pancreatic Cancer Trial Results Look Solid -- Market Talk
Dow Jones  ·  06-01 18:16
Revolution Medicines Pancreatic Cancer Trial Results Look Solid -- Market Talk
Bellevue flags Merck-Kelun Sac-TMT Phase III OptiTROP-Lung05 data as top ASCO 2026 lung cancer catalyst
Reuters  ·  06-01 16:48
Bellevue flags Merck-Kelun Sac-TMT Phase III OptiTROP-Lung05 data as top ASCO 2026 lung cancer catalyst
Why doctors stood up and cheered mid-presentation for a historic pancreatic cancer treatment
Dow Jones  ·  06-01 16:37
Why doctors stood up and cheered mid-presentation for a historic pancreatic cancer treatment
Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results
Stock Track  ·  06-01 16:07
Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--